[Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands].
The aim of present investigation was to evaluate biodistribution in healthy animals and in tumor models of the radiopharmaceuticals (99m)Tc-EDDA/tricine-HYNIC-Lys3-Bombesin (HYNIC-Lys3-BN) and (99m)Tc-NA/tricine-HYNIC-Lys3-BN. Biodistribution and pharmacokinetics were carried out over 24 hours. To do so, 24 healthy Wistar rats were used and were administered 37.0 ± 0.8 MBq/rat of each radiopharmaceutical. For the tumor model study, 20 CD-1 nude mice were used and prostate tumors (PC3) were implanted in all the mice. Ten days later, tumor volumes were calculated and 40.00 ± 0.04 MBq/mice of each radiopharmaceutical were injected. Both showed high radiochemical purity: 98.08 ± 0.25% for EDDA/tricine product and 95.1 ± 0.3% for the conjugate with NA/tricine. Uptake of the radiopharmaceutical with NA/tricine was significantly higher in organs of the reticulo-endothelial system of healthy Wistar rats during 24h, specifically in the liver and spleen. Both labeled compounds showed no significant differences between their blood elimination half lives. Average of tumor growth was 0.93 ± 0.02 cm(3) and affinity for tumors showed a growing and specific binding of both radiopharmaceuticals, although it was significantly higher for the EDDA/tricine conjugate. This outcome made it possible to corroborate the direct relationship between the density of gastrin releasing peptide and its receptors (GRPr) and the variation of the accumulation of the radiopharmaceuticals in the tumor. Use of EDDA/tricine as coligand is more appropriate than NA/tricine for labeling of HYNIC-Lys3-BN with (99m)Tc.
Centro de Investigaciones Clínicas, Ciudad Habana, La Habana, Cuba. ahcairo07@yahoo.es
A
A
Hernández-Cairo
A
A
Perera-Pintado
A
A
Prats-Capote
J F
JF
Batista-Cuellar
C
C
Casacó-Santana
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology; D000818:Animals; D001839:Bombesin / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D045744:Cell Line, Tumor / Q000637:transplantation; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D019886:Gastrin-Releasing Peptide / Q000032:analysis; D041981:Gastrointestinal Tract / Q000000981:diagnostic imaging; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D007668:Kidney / Q000000981:diagnostic imaging; D008024:Ligands; D008099:Liver / Q000000981:diagnostic imaging; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009525:Niacin / Q000493:pharmacokinetics*; D015609:Organotechnetium Compounds / Q000097:blood / Q000493:pharmacokinetics*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000097:blood / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D018004:Receptors, Bombesin / Q000032:analysis; D013154:Spleen / Q000000981:diagnostic imaging; D014018:Tissue Distribution
C512311:99mTc-EDDA-HYNIC-(Lys 3)bombesin; D008024:Ligands; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D018004:Receptors, Bombesin; D009525:Niacin; C026058:EDDA; D019886:Gastrin-Releasing Peptide; D004492:Edetic Acid; D001839:Bombesin; D005998:Glycine; C100184:tricine